Abstract 27P
Background
With the development of immune checkpoint inhibitors (ICI), microsatellite instability (MSI) has become an important biomarker. While large multigene hybrid capture next-generation sequencing (NGS) panels are highly accurate in detecting MSI, the sensitivity of small amplicon-based panels is unknown.
Methods
Next-generation sequencing (NGS) was performed on FFPE samples from patients with any stage colorectal cancer (CRC) using the Solo Atlas Pro amplicon panel covering 38 genes and 39 mononucleotide short tandem repeats for MSI analysis. 5-loci polymerase chain reaction (PCR)-based MSI analysis was used as a reference method. MSI by NGS was estimated based on the distribution of k-mers. Statistical analysis was performed using Cohen’s kappa (к), Mann Whitney and Fisher’s exact test.
Results
A total of 160 samples were analyzed using NGS and PCR. Median coverage was 2352x (range, 238-28447х), MAPD – 0.368 (range, 0.236-0.731). Based on PCR results, 42 (46.25%) samples were MSI, 118 (73.75%) – MSS. Based on NGS results, 40 (25%) samples were MSI, 120 (75%) were MSS. NGS and PCR were concordant in 98.75% (158/160) of samples (к=0.97). Sensitivity of NGS was 95.24% (95% CI, 83.84%-99.42%), specificity – 100.00% (96.92%-100.00%), accuracy – 98.75% (95.56%-99.85%). All NGS false positives cases had suboptimal FFPE quality, suggested by absence of any somatic mutations identified. MSI samples had a significantly higher amount of somatic mutations than MSS samples (median, 3 vs 1, p<0.0001). In silico mixing of the sequencing data of 11 MSI samples demonstrated that the minimal sample fraction with the detectable MSI was 0.5%; at 2.5% MSI was detectable in all samples.
Conclusions
The Atlas Pro amplicon panel demonstrates high concordance with PCR and is highly sensitive in detecting MSI in CRC samples.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Russian Science Foundation (Grant №22-75-10154).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
105P - Subsequent treatments after progression on cyclin-dependent kinase 4/6 inhibitors: A multicentric real-world data study
Presenter: Ana Rita Freitas
Session: Cocktail & Poster Display session
Resources:
Abstract
106P - Toxicity profile antibody-drug conjugates (ADCs) in metastatic breast cancer patients: A systematic review and meta-analysis based on studies’ design
Presenter: Silvia Belloni
Session: Cocktail & Poster Display session
Resources:
Abstract
107P - Receptor change on residual disease following neoadjuvant therapies for locally advanced breast cancer fails to impact oncological and survival outcomes
Presenter: Rionagh Lynch
Session: Cocktail & Poster Display session
Resources:
Abstract
114P - Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild type metastatic colorectal cancer in the CAPRI 2-GOIM trial
Presenter: Davide Ciardiello
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - Impact of tissue factor on clinical and biological characteristics in patients with advanced pancreatic cancer
Presenter: Taro Shibuki
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Multiomic profiling based on <italic>Akkermansia muciniphila</italic> in advanced non-small cell lung cancer
Presenter: Lorenzo Belluomini
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Transforming public patient omic data into precision oncology targets: A comprehensive pan-cancer approach
Presenter: Eléonore Fox
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Whole transcriptome sequencing of lung tissue to combine disease classification and identification of actionable targets
Presenter: Alejandro Pallares Robles
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - Genetic profiling of breast cancer in a developing country: Towards the establishment of oncogenetics in Cameroon
Presenter: Kenn Chi Ndi
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Uncovering the prognostic potential of FGFR2c isoform expression in advanced gastroesophageal cancer through MONSTAR-SCREEN-2 analysis
Presenter: Tadayoshi Hashimoto
Session: Cocktail & Poster Display session
Resources:
Abstract